Cystic Bronchiectasis Causes and Management

Primary Causes of Cystic Bronchiectasis

• Cystic fibrosis is one of the most common identifiable causes of bronchiectasis in the United States and Europe, occurring in 1 per 2,000-3,000 live births, caused by mutation of the gene encoding the CF transmembrane regulator protein 1
• Primary ciliary dyskinesia is a genetic disorder affecting ciliary structure and function, leading to impaired mucociliary clearance and recurrent sinopulmonary infections 1
• Alpha-1-antitrypsin deficiency can predispose to the development of bronchiectasis 2
• Connective tissue disorders like Ehlers-Danlos Syndrome and Marfan syndrome can cause bronchiectasis due to weakened bronchial walls with reduced structural integrity 3
• Allergic bronchopulmonary aspergillosis (ABPA) causes central cystic bronchiectasis due to immune-mediated inflammation in response to Aspergillus fumigatus 1
• Rheumatoid arthritis is associated with bronchiectasis in 2-5% of cases 3
• Inflammatory bowel disease can predispose to bronchiectasis development 2
• Congenital and acquired hypogammaglobulinemia (especially IgG and/or IgG subclasses) can cause bronchiectasis 2
• HIV infection can cause bronchiectasis 4, 2
• Chronic Mycobacterium avium complex (MAC) infection, particularly in white women in their seventh or eighth decade, can cause bronchiectasis 1
• Prior severe pneumonia or tuberculosis can cause bronchiectasis 2
• Recurrent bacterial infections leading to progressive airway injury can cause bronchiectasis 2
• Bronchial obstruction by foreign bodies, tumors, broncholithiasis, or compression by peribronchial lymph nodes can cause bronchiectasis 2
• Post-pneumonia focal damage can cause bronchiectasis 2
• Tracheobronchomegaly (Mounier-Kuhn syndrome) can cause bronchiectasis 2
• Cartilage deficiency (Williams-Campbell syndrome) can cause bronchiectasis 2
• Yellow nail syndrome can cause bronchiectasis 2
• Aspiration or toxic inhalation can cause bronchiectasis 2

Pathophysiology of Cystic Bronchiectasis

• Bronchiectasis involves a vicious cycle of chronic bronchial infection, inflammation, impaired mucociliary clearance, and structural lung damage 5
• Recurrent bacterial colonization and infection lead to progressive airway injury mediated by neutrophils, T lymphocytes, and monocyte-derived cytokines 2
• Inflammatory mediators, elastase, and collagenase cause destruction of the elastic and muscular components of bronchial walls 2
• The contractile force of surrounding lung tissue exerts traction, expanding the diameter of involved airways 2
• Increased bronchial arterial proliferation and arteriovenous malformations can predispose to recurrent hemoptysis 2

Diagnostic Approach

• High-resolution CT scanning is the diagnostic procedure of choice to confirm bronchiectasis, with sensitivity and specificity exceeding 90% 1
• Key features on HRCT include enlarged internal bronchial diameter, failure of larger airways to taper while progressing to the lung periphery, and air-fluid levels in dilated airways 1
• Central distribution of bronchiectasis is often seen in ABPA 1

Clinical Implications and Management

• Early diagnosis and intervention are important to potentially reverse bronchial wall dilatation in early disease 1, 5
• Treatment should target the underlying cause when identified 1
• For ABPA, corticosteroid treatment may be beneficial 1
• For MAC infection, treatment with a macrolide, ethambutol, and a rifamycin is considered first-line therapy 1
• Airway clearance techniques offer a modest benefit in increasing sputum volume 4, 2
• Selected patients with localized bronchiectasis causing intolerable symptoms despite maximal medical therapy should be considered for surgical treatment 4, 2
• Exacerbations should be treated with appropriate antibiotics based on likely causative pathogens 4, 2

Etiology of Bronchiectasis: Evidence‑Based Causes

Infectious Causes

• Bacterial pneumonia, especially in childhood, is a well‑established cause of permanent bronchial wall damage leading to bronchiectasis (American Thoracic Society evidence, Level C) 6, 7, 8.
• Acute pulmonary infection destroys elastic and muscular components of the bronchial wall, resulting in irreversible airway dilation (American Thoracic Society, Level C) 9.
• Healed pulmonary tuberculosis can produce traction bronchiectasis through fibrotic remodeling that pulls on major airways, predisposing to recurrent infection (American Thoracic Society, Level C) 6, 7, 8.
• In patients with prior tuberculosis, surrounding fibrosis creates traction on airways, distorting architecture and causing bronchiectasis (American Thoracic Society, Level C) 6, 7.

Genetic and Congenital Causes

• Cystic fibrosis is the most common identifiable cause of bronchiectasis in high‑income regions, with an incidence of approximately 1 per 2,000–3,000 live births (American Thoracic Society, Level B) 6, 7, 8.
• Cystic fibrosis accounts for 3–4 % of adult patients presenting with bronchiectasis (American Thoracic Society, Level B) 10.
• CFTR gene mutations lead to thick, tenacious mucus, impaired mucociliary clearance, and proximal airway plugging, which culminate in bronchiectasis (American Thoracic Society, Level B) 6.

Other Identified Causes

• Immunodeficiency (e.g., hypogammaglobulinemia) is identified in about 7 % of bronchiectasis cases (American Thoracic Society, Level C) 10.
• Allergic bronchopulmonary aspergillosis contributes to roughly 4 % of bronchiectasis cases (American Thoracic Society, Level C) 10.
• Primary ciliary dyskinesia is responsible for ≤5 % of bronchiectasis cases (American Thoracic Society, Level C) 10.

Diagnostic Recommendations

• A systematic search for underlying etiologies should be performed in every patient with bronchiectasis; causative factors are identified in ~47 % of patients, with prognostic or therapeutic relevance in ~15 % (American Thoracic Society, Level C) 6, 7.
• The most frequently identified overall causes are cystic fibrosis (dominant in developed countries) and post‑infectious damage (including pneumonia, pertussis, measles, and tuberculosis) (American Thoracic Society, Level C) 6, 8, 7.